Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Zhai, S., Liu, C., Vimalraj, S., Subramanian, R., Abullais, S
Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs
Bloody diarrhea, black tarry stools, severe abdominal cramping, or vomiting warrant medical evaluation
Available online at: (Accessed 28, October, 2025)
When you take a GLP-1 receptor agonist, you are essentially giving your body a more powerful, longer-lasting version of this signal
At 0.25mg for 4 weeks then 0.5mg for 4 weeks, you use 3mg total from the 5mg vial
